LW
Therapeutic Areas
Daré Bioscience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DARE to PLAY™ (Sildenafil Cream) | Female Sexual Arousal Disorder | Approved |
| Ovaprene® | Hormone-Free Contraception | Phase 3 |
| DARE-HPV1 | Persistent High-Risk HPV Infection | Phase 2 |
| DARE to RESTORE™ (DARE-BV1) | Bacterial Vaginosis / Vaginal Microbiome | Phase 2b |
| DARE to RECLAIM™ (DARE-FRT1) | Vaginal Dryness (Menopause) | Phase 2 |
| DARE to PLAN™ (DARE-LAI1) | Long-Acting Injectable Contraception | Phase 1 |
| DARE to FIGHT™ (DARE-VVD1) | Recurrent Vulvovaginal Candidiasis | Preclinical |
| DARE to SUPPORT™ | Pregnancy Support | Not Disclosed |
Leadership Team at Daré Bioscience
SM
Sabrina Martucci Johnson
Founder, President, Chief Executive Officer & Director
JA
John A. Fair
Chief Business and Strategy Officer
DL
David L. Friend
Chief Development Officer
TF
Tara Frenkl
Chief Medical Officer
GW
Gregory W. Matz
Senior Vice President, Pharmaceutical Development